Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02874404
Title TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Recruitment Completed
Gender
Phase Phase II
Variant Requirements No
Sponsors Matthew Lunning, MD
Indications

diffuse large B-cell lymphoma

Therapies

Ibrutinib + Umbralisib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.